The Carcinogenic Agent Azoxymethane (AOM) Enhances Early Inflammation-induced Colon Crypt Pathology
- *Corresponding Author:
- Mogens H Claesson
Professor, DMSc, The Panum Institute
Blegdamsvej 3, 2200 Copenhagen, Denmark
Tel: 45 35327270
Fax: 45 35327269
E-mail: [email protected]
Received Date: August 31, 2013; Accepted Date: October 24, 2013; Published Date: October 28, 2013
Citation: Venning FA, Claesson MH, Kissow H (2013) The Carcinogenic Agent Azoxymethane (AOM) Enhances Early Inflammation-induced Colon Crypt Pathology. J Cancer Sci Ther 5:377-383. doi:10.4172/1948-5956.1000229
Copyright: © 2013 Venning FA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Severe combined immunodeficiency (SCID) mice transplanted with CD4+ T cells depleted of CD25+ regulatory T cells develop colitis within 2-3 weeks after the T cell transfer. In the present study we studied the effect of the carcinogen azoxymethane (AOM) on the colon crypt pathology of normal SCID mice and SCID mice with transfer colitis. AOM by itself did result in neither weight loss nor inflammation although treatment affected crypt widths and numbers. Although AOM together with T cell transfer did not increase the level of gut inflammation including COX-2 expression, AOM increased crypt changes associated with colon inflammation such as a decline in crypt numbers and an increase in crypts width throughout the large intestine. Thus it appears that AOM lower the threshold level for inflammation-induced changes which potentially may lead to neoplasia.